肾嗜酸细胞瘤的分子病理学:综述。
Molecular pathology of renal oncocytoma: a review.
机构信息
Laboratory of Molecular Oncology, Medical Faculty, Ruprecht-Karls University, Heidelberg, Germany.
出版信息
Int J Urol. 2010 Jul;17(7):602-12. doi: 10.1111/j.1442-2042.2010.02574.x.
Differentiating renal oncocytoma from its renal cell carcinoma (RCC) mimics, particularly chromophobe RCC, can be difficult, especially when limited tissue is available for evaluation and requires sophisticated microscopic, ultrastructural and immunohistochemical evaluation. In this review, the relevant literature has been reviewed, and supporting data obtained by applying modern microarray-based technologies are discussed with a focus on molecular pathology of renal oncocytoma. The high resolution whole-genome DNA-microarray based analyses excluded with all certainty the occurrence of small specific alterations. Renal oncocytomas are characterized by variable chromosomal patterns. The number of genes selected by global gene expression analyses and their usefulness in the diagnostic pathology based on immunohistochemical evaluation is far below the expectations. The conflicting staining patterns, together with the poor specificity of proposed antibodies, leads us to believe that these candidate immunomarkers might not help in the separation of these tumors. Applying DNA based tools might help in the diagnosis of renal oncocytoma with uncertain histology. However, only the combination of all available techniques could give reliable information.
鉴别肾嗜酸细胞瘤与其肾细胞癌(RCC)模拟物,特别是嫌色细胞 RCC,可能具有挑战性,特别是当可用于评估的组织有限且需要复杂的显微镜、超微结构和免疫组织化学评估时。在这篇综述中,我们回顾了相关文献,并讨论了应用现代基于微阵列的技术获得的支持数据,重点是肾嗜酸细胞瘤的分子病理学。高分辨率全基因组 DNA 微阵列分析确定地排除了小的特定改变的发生。肾嗜酸细胞瘤的特点是可变的染色体模式。通过全局基因表达分析选择的基因数量及其在基于免疫组织化学评估的诊断病理学中的有用性远低于预期。有冲突的染色模式,加上提出的抗体的特异性差,使我们相信这些候选免疫标志物可能无助于这些肿瘤的分离。应用基于 DNA 的工具可能有助于诊断具有不确定组织学的肾嗜酸细胞瘤。然而,只有结合所有可用技术才能提供可靠的信息。